Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Segment Information and Revenue Recognition (Details)

v3.8.0.1
Summary of Significant Accounting Policies - Segment Information and Revenue Recognition (Details)
$ in Millions
3 Months Ended
Mar. 31, 2018
USD ($)
segment
Mar. 31, 2017
USD ($)
Number of operating segments | segment 1  
Revenue $ 0.4  
Collaboration Agreement | Incyte    
Revenue $ 0.4  
Research Agreement | Multinational Pharmaceutical Company | Before topic 606    
Revenue   $ 1.1